These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

802 related articles for article (PubMed ID: 10781674)

  • 1. Antithrombotic and hemostatic capacity of factor Xa versus thrombin inhibitors in models of venous and arteriovenous thrombosis.
    Sinha U; Ku P; Malinowski J; Zhu BY; Scarborough RM; Marlowe CK; Wong PW; Lin PH; Hollenbach SJ
    Eur J Pharmacol; 2000 Apr; 395(1):51-9. PubMed ID: 10781674
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A comparative study of prothrombinase and thrombin inhibitors in a novel rabbit model of non-occlusive deep vein thrombosis.
    Hollenbach S; Sinha U; Lin PH; Needham K; Frey L; Hancock T; Wong A; Wolf D
    Thromb Haemost; 1994 Mar; 71(3):357-62. PubMed ID: 8029801
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The antithrombotic effects of CI-1031 (ZK-807834) and enoxaparin in a canine electrolytic injury model of arterial and venous thrombosis.
    McClanahan TB; Hicks GW; Morrison AL; Peng YW; Janiczek-Dolphin N; Mertz TE; Sullivan ME; Morser J; Juneau PL; Leadley R
    Eur J Pharmacol; 2001 Dec; 432(2-3):187-94. PubMed ID: 11740955
    [TBL] [Abstract][Full Text] [Related]  

  • 4. An algal sulfated galactan has an unusual dual effect on venous thrombosis due to activation of factor XII and inhibition of the coagulation proteases.
    Melo FR; Mourão PA
    Thromb Haemost; 2008 Mar; 99(3):531-8. PubMed ID: 18327401
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Activity of a sub-cutaneously administered novel mixed micellar formulation of argatroban in rat and rabbit models of venous thrombosis.
    Berry CN; Visconte C; Lecoffre C; Lochot S; Girard D
    Thromb Haemost; 2000 Aug; 84(2):286-90. PubMed ID: 10959702
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Evaluation of AR-H067637, the active metabolite of the new direct thrombin inhibitor AZD0837, in models of venous and arterial thrombosis and bleeding in anaesthetised rats.
    Pehrsson S; Johansson K; Kjaer M; Elg M
    Thromb Haemost; 2010 Dec; 104(6):1242-9. PubMed ID: 20806126
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Anticoagulants (thrombin inhibitors) and aspirin synergize with P2Y12 receptor antagonism in thrombosis.
    André P; LaRocca T; Delaney SM; Lin PH; Vincent D; Sinha U; Conley PB; Phillips DR
    Circulation; 2003 Nov; 108(21):2697-703. PubMed ID: 14597584
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Thrombin inhibitors and anti-coagulants on thrombin-induced embolisation in rabbit cranial vasculature.
    Liu JT; Paul W; Emerson M; Cicala C; Page CP
    Eur J Pharmacol; 1994 Oct; 264(2):183-90. PubMed ID: 7851481
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Nonpeptide factor Xa inhibitors III: effects of DPC423, an orally-active pyrazole antithrombotic agent, on arterial thrombosis in rabbits.
    Wong PC; Crain EJ; Watson CA; Zaspel AM; Wright MR; Lam PY; Pinto DJ; Wexler RR; Knabb RM
    J Pharmacol Exp Ther; 2002 Dec; 303(3):993-1000. PubMed ID: 12438519
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of a factor Xa inhibitor, DX-9065a, in a novel rabbit model of venous thrombosis.
    Rogers KL; Chi L; Rapundalo ST; Kramer JB; Gallagher KP
    Basic Res Cardiol; 1999 Feb; 94(1):15-22. PubMed ID: 10097826
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of antithrombotic and hemorrhagic effects of edoxaban, a novel factor Xa inhibitor, with unfractionated heparin, dalteparin, lepirudin and warfarin in rats.
    Morishima Y; Honda Y; Kamisato C; Shibano T
    Thromb Res; 2013 Aug; 132(2):234-9. PubMed ID: 23768448
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Antithrombotic actions of argatroban in rat models of venous, 'mixed' and arterial thrombosis, and its effects on the tail transection bleeding time.
    Berry CN; Girard D; Lochot S; Lecoffre C
    Br J Pharmacol; 1994 Dec; 113(4):1209-14. PubMed ID: 7889274
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Dissociation of antithrombotic effect and bleeding time prolongation in rabbits by inhibiting tissue factor function.
    Himber J; Kirchhofer D; Riederer M; Tschopp TB; Steiner B; Roux SP
    Thromb Haemost; 1997 Sep; 78(3):1142-9. PubMed ID: 9308768
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Antithrombotic activity of recombinant tick anticoagulant peptide and heparin in a rabbit model of venous thrombosis.
    Fioravanti C; Burkholder D; Francis B; Siegl PK; Gibson RE
    Thromb Res; 1993 Aug; 71(4):317-24. PubMed ID: 8236160
    [TBL] [Abstract][Full Text] [Related]  

  • 15. In vitro and in vivo studies of the novel antithrombotic agent BAY 59-7939--an oral, direct Factor Xa inhibitor.
    Perzborn E; Strassburger J; Wilmen A; Pohlmann J; Roehrig S; Schlemmer KH; Straub A
    J Thromb Haemost; 2005 Mar; 3(3):514-21. PubMed ID: 15748242
    [TBL] [Abstract][Full Text] [Related]  

  • 16. In vitro and in vivo antithrombotic activity of PD-198961, a novel synthetic factor Xa inhibitor.
    Chi L; Peng YW; Gibson G; Hicks G; Mertz TE; Rapundalo S; Janiczek N; Edmunds JJ; Leadley R
    J Cardiovasc Pharmacol; 2004 Oct; 44(4):493-500. PubMed ID: 15454859
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Relationship between the antithrombotic effect of YM-75466, a novel factor Xa inhibitor, and coagulation parameters in rats.
    Sato K; Taniuchi Y; Kawasaki T; Hirayama F; Koshio H; Matsumoto Y
    Eur J Pharmacol; 1998 Apr; 347(2-3):231-6. PubMed ID: 9653887
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparison of enoxaparin, hirulog, and heparin as adjunctive antithrombotic therapy during thrombolysis with rtPA in the stenosed canine coronary artery.
    Leadley RJ; Kasiewski CJ; Bostwick JS; Bentley R; McVey MJ; White FJ; Perrone MH; Dunwiddie CT
    Thromb Haemost; 1997 Oct; 78(4):1278-85. PubMed ID: 9364998
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparison of thrombin active site and exosite inhibitors and heparin in experimental models of arterial and venous thrombosis and bleeding.
    Schumacher WA; Steinbacher TE; Heran CL; Seiler SM; Michel IM; Ogletree ML
    J Pharmacol Exp Ther; 1993 Dec; 267(3):1237-42. PubMed ID: 8263785
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Impact of antithrombin deficiency on efficacy of edoxaban and antithrombin-dependent anticoagulants, fondaparinux, enoxaparin, and heparin.
    Fukuda T; Kamisato C; Honda Y; Matsushita T; Kojima T; Furugohri T; Morishima Y; Shibano T
    Thromb Res; 2013 Jun; 131(6):540-6. PubMed ID: 23673387
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 41.